Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

629
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
629
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients.

EBioMedicine·2018
Same author

Relationship between pre-exercise muscle stiffness and muscle damage induced by eccentric exercise.

European journal of sport science·2018
Same author

Deoxynivalenol decreased intestinal immune function related to NF-κB and TOR signalling in juvenile grass carp (Ctenopharyngodon idella).

Fish & shellfish immunology·2018
Same author

Hypermethylation of miR-338-3p and Impact of its Suppression on Cell Metastasis Through N-Cadherin Accumulation at the Cell -Cell Junction and Degradation of MMP in Gastric Cancer.

Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology·2018
Same author

Reference genes selection for quantitative gene expression studies in tea green leafhoppers, Empoasca onukii Matsuda.

PloS one·2018
Same author

Urinary phthalate metabolites in relation to childhood asthmatic and allergic symptoms in Shanghai.

Environment international·2018

Related Experiment Video

Updated: Aug 18, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

594

Holistic immunomodulation for small cell lung cancer.

Elaine Lai-Han Leung1, Xing-Xing Fan2, Ju-Min Huang1

  • 1Cancer Center, Faculty of Health Sciences, University of Macau, Macao Special Administrative Region of China; MOE Frontiers Science Center for Precision Oncology, University of Macau, Macao Special Administrative Region of China.

Seminars in Cancer Biology
|December 5, 2022
PubMed
Summary

Novel therapies like CAR T-cell therapy, immunomodulating antibodies, traditional Chinese medicines, and microbiota offer new hope for treating small cell lung cancer (SCLC). These approaches, alongside multiomics, aim to improve patient outcomes and survival rates.

Keywords:
CARImmunotherapySCLCTCMTargetTherapeutic strategies

More Related Videos

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

972
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K

Related Experiment Videos

Last Updated: Aug 18, 2025

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

594
Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
07:55

Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer

Published on: January 17, 2025

972
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.2K

Area of Science:

  • Oncology
  • Immunotherapy
  • Pharmacology

Background:

  • Small cell lung cancer (SCLC) presents a significant clinical challenge due to its aggressive nature, high mortality, and limited treatment options.
  • The poor prognosis associated with SCLC necessitates the exploration of innovative therapeutic strategies and agents.

Purpose of the Study:

  • To provide a comprehensive review of emerging therapeutic targets, agents, and strategies for SCLC treatment.
  • To evaluate the potential and challenges of novel approaches including chimeric antigen receptor (CAR) T therapy, immunomodulating antibodies, traditional Chinese medicines (TCMs), and the microbiota.
  • To discuss the role of multiomics technologies in SCLC diagnostics and drug discovery.

Main Methods:

  • Literature review and synthesis of current research on SCLC therapeutics.
  • Analysis of novel treatment modalities such as CAR T therapy, immunomodulating antibodies, TCMs, and microbiota.
  • Exploration of multiomics integration for diagnostic and therapeutic target identification.

Main Results:

  • Emerging strategies like CAR T therapy, immunomodulating antibodies, TCMs, and microbiota show promise in improving clinical outcomes for SCLC.
  • Multiomics technologies offer potential for developing advanced diagnostic methods and identifying new drug targets.
  • Combinational treatments involving these novel strategies may provide enhanced efficacy for SCLC.

Conclusions:

  • Novel therapeutic avenues, including immunotherapy, TCMs, and microbiota modulation, represent promising alternatives for SCLC treatment.
  • Integrating multiomics approaches can accelerate the discovery of new diagnostic tools and therapeutic targets for SCLC.
  • Further research into combinational therapies is crucial for maximizing the clinical benefit in SCLC management.